Viimane versioon :
08/05/2024
Antihüpertensiivne ravim   Hydralazine hydrochloride  
Süsteravim
Suukaudne lahus
Stabiilsus lahustes Stabiilsust mõjutavad tegurid Stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited Pdf
Liposoom   Keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Apresoline Kanada
Hydralazine Ameerika ühendriigid, Hispaania, Suurbritannia
Hydrapres Hispaania
Viited   Süsteravim   Viited : Hydralazine hydrochloride  
Tüüp Avaldamine
660 Ajaleht Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
957 Ajaleht Halasi S, Nairn JG.
Stability studies of hydralazine in aqueous solutions.
J Parenter Sci Technol 1990 ; 44: 30-34.
1049 Ajaleht Klamerus KJ, Ueda CT, Newton DW.
Stability of nitroglycerin in intravenous admixtures.
Am J Hosp Pharm 1984 ; 41: 303-305.
1057 Ajaleht Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1173 Ajaleht Kowaluk EA, Roberts MS, Blackburn HD, Polack AE.
Interactions between drugs and polyvinyl chloride infusion bags.
Am J Hosp Pharm 1981 ; 38: 1308-1314.
1221 Ajaleht Dahlin PA, Paredes SM.
Visual compatibility of dobutamine with seven parenteral drug products.
Am J Hosp Pharm 1980 ; 37: 460,464.
1228 Ajaleht Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
2090 Ajaleht Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2233 Ajaleht Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2367 Ajaleht Gupta V.D.
Chemical stability of hydralazine hydrochloride after reconstitution in 0.9% sodium chloride injection or 5% dextrose injection for infusion.
Int J Pharm Compound 2005 ; 9, 5: 399-401.
3012 Ajaleht Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3408 Ajaleht Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3766 Ajaleht Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3964 Ajaleht Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4319 Ajaleht Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 Ajaleht Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4603 Ajaleht Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.

  Mentions Légales